<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863953</url>
  </required_header>
  <id_info>
    <org_study_id>192024-082</org_study_id>
    <nct_id>NCT01863953</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared
      with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Day 42</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Eye Mean Diurnal IOP</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Eye Mean Diurnal IOP</measure>
    <time_frame>Day 14, Day 28, Day 42</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Fixed-Combination Bimatoprost/Brimonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine Tartrate Ophthalmic Solution 0.2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-Combination Bimatoprost/Brimonidine</intervention_name>
    <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
    <arm_group_label>Fixed-Combination Bimatoprost/Brimonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Ophthalmic Solution 0.01%</intervention_name>
    <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.</description>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
    <other_name>LUMIGAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution</intervention_name>
    <description>One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
    <arm_group_label>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate Ophthalmic Solution 0.2%</intervention_name>
    <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
    <arm_group_label>Brimonidine Tartrate Ophthalmic Solution 0.2%</arm_group_label>
    <other_name>ALPHAGAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ocular hypertension or glaucoma

          -  Requires intraocular pressure (IOP)-lowering therapy

        Exclusion Criteria:

          -  Cataract surgery in one eye

          -  Ocular laser or intraocular surgery within 6 months

          -  Refractive surgery in either eye

          -  Anticipated use of contact lenses during the study

          -  Expected use of artificial tears during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <results_first_submitted>January 16, 2015</results_first_submitted>
  <results_first_submitted_qc>January 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>January 16, 2015</last_update_submitted>
  <last_update_submitted_qc>January 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fixed-Combination Bimatoprost/Brimonidine</title>
          <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
          <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
          <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fixed-Combination Bimatoprost/Brimonidine</title>
          <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
          <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
          <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
        <time_frame>Baseline, Day 42</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed-Combination Bimatoprost/Brimonidine</title>
            <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
            <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
            <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
          <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" spread="1.712"/>
                    <measurement group_id="O2" value="24.38" spread="2.022"/>
                    <measurement group_id="O3" value="24.29" spread="1.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 42 (N=38, 36, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="2.277"/>
                    <measurement group_id="O2" value="-6.63" spread="2.284"/>
                    <measurement group_id="O3" value="-3.92" spread="2.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Eye Mean Diurnal IOP</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
        <time_frame>Baseline, Day 14, Day 28</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed-Combination Bimatoprost/Brimonidine</title>
            <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
            <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
            <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Eye Mean Diurnal IOP</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).</description>
          <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" spread="1.712"/>
                    <measurement group_id="O2" value="24.38" spread="2.022"/>
                    <measurement group_id="O3" value="24.29" spread="1.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.63" spread="2.152"/>
                    <measurement group_id="O2" value="-6.79" spread="1.997"/>
                    <measurement group_id="O3" value="-4.67" spread="2.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="2.328"/>
                    <measurement group_id="O2" value="-6.98" spread="2.260"/>
                    <measurement group_id="O3" value="-4.22" spread="2.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Eye Mean Diurnal IOP</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12.</description>
        <time_frame>Day 14, Day 28, Day 42</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed-Combination Bimatoprost/Brimonidine</title>
            <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
            <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
            <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Eye Mean Diurnal IOP</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12.</description>
          <population>Modified Intent to Treat: all randomized and treated patients who had baseline and at least 1 postbaseline IOP assessment</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.91" spread="2.004"/>
                    <measurement group_id="O2" value="17.59" spread="2.363"/>
                    <measurement group_id="O3" value="19.61" spread="2.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.29" spread="2.588"/>
                    <measurement group_id="O2" value="17.40" spread="2.549"/>
                    <measurement group_id="O3" value="20.06" spread="2.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (N=38, 36, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" spread="2.505"/>
                    <measurement group_id="O2" value="17.76" spread="2.467"/>
                    <measurement group_id="O3" value="20.34" spread="2.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Treatment emergent adverse events (TEAE) are reported and include all adverse events (AEs) and serious adverse events (SAEs) that began or worsened after study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fixed-Combination Bimatoprost/Brimonidine</title>
          <description>One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Bimatoprost Ophthalmic Solution 0.01% and Vehicle</title>
          <description>One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Brimonidine Tartrate Ophthalmic Solution 0.2%</title>
          <description>One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Instillation Site Lacrimation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

